Kevin Barvian
Blueprint Medicines (United States)(US)
Publications by Year
Research Areas
Cancer therapeutics and mechanisms, Sarcoma Diagnosis and Treatment, Lung Cancer Treatments and Mutations, Reproductive tract infections research, Gastrointestinal Tumor Research and Treatment
Most-Cited Works
- → Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases(2015)100 cited
- → Abstract 1262: BLU-701 is a highly potent, brain-penetrant and WT-sparing next-generation EGFR TKI for the treatment of sensitizing (ex19del, L858R) and C797S resistance mutations in metastatic NSCLC(2021)24 cited
- → BLU-701 tumour suppression and intracranial activity as a single agent and in combination with BLU-945 in models of non-small cell lung cancer (NSCLC) driven by EGFR mutations(2022)3 cited
- → Correction: Corrigendum: Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases(2015)2 cited
- → Abstract LB565: Efficacy of a highly potent and selective KIT V654A inhibitor for treatment of imatinib resistant GIST(2022)
- → Design and Synthesis of BLU-654, a Potent and Selective Mutant KIT V654A Inhibitor for the Treatment of Imatinib-Resistant GIST(2026)